Published in Hepatology on November 01, 2007
Living in the liver: hepatic infections. Nat Rev Immunol (2012) 2.03
IL-10-producing regulatory B cells in the pathogenesis of chronic hepatitis B virus infection. J Immunol (2012) 1.47
Peripheral virus-specific T-cell interleukin-10 responses develop early in acute hepatitis C infection and become dominant in chronic hepatitis. J Hepatol (2008) 1.22
Impaired quality of the hepatitis B virus (HBV)-specific T-cell response in human immunodeficiency virus type 1-HBV coinfection. J Virol (2009) 0.99
Therapeutic vaccines in HBV: lessons from HCV. Med Microbiol Immunol (2015) 0.93
Cellular immune responses in patients with hepatitis B surface antigen seroclearance induced by antiviral therapy. Virol J (2011) 0.92
HIV and co-infections. Immunol Rev (2013) 0.92
Natural killer cells are characterized by the concomitantly increased interferon-γ and cytotoxicity in acute resolved hepatitis B patients. PLoS One (2012) 0.87
No increase in hepatitis B virus (HBV)-specific CD8+ T cells in patients with HIV-1-HBV coinfections following HBV-active highly active antiretroviral therapy. J Virol (2010) 0.87
HBV-Specific Adaptive Immunity. Viruses (2009) 0.85
TCRγδ(+)CD4(-)CD8(-) T cells suppress the CD8(+) T-cell response to hepatitis B virus peptides, and are associated with viral control in chronic hepatitis B. PLoS One (2014) 0.76
Modeling and simulating dynamics of complete- and poor-response chronic hepatitis B chinese patients for adefovir and traditional chinese medicine plus adefovir therapy. Evid Based Complement Alternat Med (2013) 0.75
Increased CD86 but Not CD80 and PD-L1 Expression on Liver CD68+ Cells during Chronic HBV Infection. PLoS One (2016) 0.75
Dynamic Perturbations of CD4 and CD8 T Cell Receptor Repertoires in Chronic Hepatitis B Patients upon Oral Antiviral Therapy. Front Immunol (2017) 0.75
Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis (2011) 7.41
Towards an HIV cure: a global scientific strategy. Nat Rev Immunol (2012) 5.52
Diversity of receptors binding HIV on dendritic cell subsets. Nat Immunol (2002) 4.63
The end of AIDS: HIV infection as a chronic disease. Lancet (2013) 3.96
Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med (2014) 3.40
Immunodeficiency virus uptake, turnover, and 2-phase transfer in human dendritic cells. Blood (2003) 3.40
Rapid viral escape at an immunodominant simian-human immunodeficiency virus cytotoxic T-lymphocyte epitope exacts a dramatic fitness cost. J Virol (2005) 3.03
Long-lived epithelial immunity by tissue-resident memory T (TRM) cells in the absence of persisting local antigen presentation. Proc Natl Acad Sci U S A (2012) 2.64
Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia. J Hepatol (2010) 2.61
Perinatal transmission of hepatitis B virus: an Australian experience. Med J Aust (2009) 2.42
The CD16+ monocyte subset is more permissive to infection and preferentially harbors HIV-1 in vivo. J Immunol (2007) 2.41
Toll-like receptors, RIG-I-like RNA helicases and the antiviral innate immune response. Immunol Cell Biol (2007) 2.24
Immunopathogenesis of hepatic flare in HIV/hepatitis B virus (HBV)-coinfected individuals after the initiation of HBV-active antiretroviral therapy. J Infect Dis (2009) 2.24
CCR7 ligands CCL19 and CCL21 increase permissiveness of resting memory CD4+ T cells to HIV-1 infection: a novel model of HIV-1 latency. Blood (2007) 2.21
ITPA genotype protects against anemia during peginterferon and ribavirin therapy but does not influence virological response. Hepatology (2014) 2.12
Establishment of HIV-1 latency in resting CD4+ T cells depends on chemokine-induced changes in the actin cytoskeleton. Proc Natl Acad Sci U S A (2010) 2.07
Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology (2010) 2.02
Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity antibodies in the absence of neutralizing antibodies. J Immunol (2013) 1.95
Capsule endoscopy vs. push enteroscopy and enteroclysis in suspected small-bowel Crohn's disease. Gastrointest Endosc (2005) 1.95
Robust NK cell-mediated human immunodeficiency virus (HIV)-specific antibody-dependent responses in HIV-infected subjects. J Virol (2008) 1.83
Pharmacy adherence measures to assess adherence to antiretroviral therapy: review of the literature and implications for treatment monitoring. Clin Infect Dis (2011) 1.77
IMGT/HighV QUEST paradigm for T cell receptor IMGT clonotype diversity and next generation repertoire immunoprofiling. Nat Commun (2013) 1.71
Hepatitis B virus and hepatitis C virus interaction in Huh-7 cells. J Hepatol (2009) 1.67
Biological determinants of immune reconstitution in HIV-infected patients receiving antiretroviral therapy: the role of interleukin 7 and interleukin 7 receptor α and microbial translocation. J Infect Dis (2010) 1.63
Peripheral blood mononuclear cell expression of toll-like receptors and relation to cytokine levels in cirrhosis. Hepatology (2003) 1.59
HDAC inhibitors in HIV. Immunol Cell Biol (2011) 1.59
Immune escape from HIV-specific antibody-dependent cellular cytotoxicity (ADCC) pressure. Proc Natl Acad Sci U S A (2011) 1.58
Rapid degranulation of NK cells following activation by HIV-specific antibodies. J Immunol (2009) 1.57
Lamivudine resistance in patients with chronic hepatitis B: role of clinical and virological factors. J Gastroenterol Hepatol (2007) 1.54
Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy. Virology (2002) 1.53
Comparison of HDAC inhibitors in clinical development: effect on HIV production in latently infected cells and T-cell activation. Hum Vaccin Immunother (2013) 1.53
Antibody-dependent cellular cytotoxicity is associated with control of pandemic H1N1 influenza virus infection of macaques. J Virol (2013) 1.53
Analysis of pigtail macaque major histocompatibility complex class I molecules presenting immunodominant simian immunodeficiency virus epitopes. J Virol (2005) 1.52
A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand. Hepatology (2008) 1.52
The anti-HIV activity of entecavir: a multicentre evaluation of lamivudine-experienced and lamivudine-naive patients. AIDS (2008) 1.50
Immunopathogenesis of hepatitis B virus infection. Immunol Cell Biol (2006) 1.47
Clinical and mycological predictors of cryptococcosis-associated immune reconstitution inflammatory syndrome. AIDS (2013) 1.46
Epidemiology of sepsis in Victoria, Australia. Crit Care Med (2005) 1.44
Staphylococcal toxic shock syndrome: still a problem. Med J Aust (2005) 1.43
CD4+ T-cell deficiency in HIV patients responding to antiretroviral therapy is associated with increased expression of interferon-stimulated genes in CD4+ T cells. J Infect Dis (2011) 1.40
The evidence for a change in antenatal HIV screening policy in Australia. Med J Aust (2006) 1.40
Regulation of Toll-like receptor-2 expression in chronic hepatitis B by the precore protein. Hepatology (2007) 1.38
Variable uptake of recommended interventions to reduce mother-to-child transmission of HIV in Australia, 1982-2005. Med J Aust (2008) 1.37
Vaccination and timing influence SIV immune escape viral dynamics in vivo. PLoS Pathog (2008) 1.34
Toll-like receptors and their role in gastrointestinal disease. J Gastroenterol Hepatol (2009) 1.34
A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1. AIDS (2006) 1.33
Both CD31(+) and CD31⁻ naive CD4(+) T cells are persistent HIV type 1-infected reservoirs in individuals receiving antiretroviral therapy. J Infect Dis (2010) 1.33
The intracellular granzyme B inhibitor, proteinase inhibitor 9, is up-regulated during accessory cell maturation and effector cell degranulation, and its overexpression enhances CTL potency. J Immunol (2003) 1.32
Expression and reactivation of HIV in a chemokine induced model of HIV latency in primary resting CD4+ T cells. Retrovirology (2011) 1.31
The utility of ADCC responses in HIV infection. Curr HIV Res (2008) 1.30
Resistance to anti-HCV protease inhibitors. Curr Opin Virol (2011) 1.30
Fatal case of toxic shock-like syndrome due to group C streptococcus associated with superantigen exotoxin. J Clin Microbiol (2004) 1.29
Antiviral drug resistance: clinical consequences and molecular aspects. Semin Liver Dis (2006) 1.27
A systematic review of T-cell epitopes in hepatitis B virus: identification, genotypic variation and relevance to antiviral therapeutics. Antivir Ther (2008) 1.25
Activation of NK cells by ADCC antibodies and HIV disease progression. J Acquir Immune Defic Syndr (2011) 1.24
Persistent immune activation in chronic HIV infection: do any interventions work? AIDS (2013) 1.24
Reduced hepatitis B virus (HBV)-specific CD4+ T-cell responses in human immunodeficiency virus type 1-HBV-coinfected individuals receiving HBV-active antiretroviral therapy. J Virol (2005) 1.23
High levels of human antigen-specific CD4+ T cells in peripheral blood revealed by stimulated coexpression of CD25 and CD134 (OX40). J Immunol (2009) 1.22
MHC class I allele frequencies in pigtail macaques of diverse origin. Immunogenetics (2006) 1.21
Simian immunodeficiency virus infects follicular helper CD4 T cells in lymphoid tissues during pathogenic infection of pigtail macaques. J Virol (2013) 1.21
Comparative evaluation of simian, simian-human, and human immunodeficiency virus infections in the pigtail macaque (Macaca nemestrina) model. AIDS Res Hum Retroviruses (2006) 1.21
Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro. Hepatology (2003) 1.21
Immune restoration diseases reflect diverse immunopathological mechanisms. Clin Microbiol Rev (2009) 1.21
Identification of lineage relationships and novel markers of blood and skin human dendritic cells. J Immunol (2012) 1.21
Specific antibody-dependent cellular cytotoxicity responses associated with slow progression of HIV infection. Immunology (2013) 1.19
Vaccine-induced T cells control reversion of AIDS virus immune escape mutants. J Virol (2007) 1.19
Chemokine levels and chemokine receptor expression in the blood and the cerebrospinal fluid of HIV-infected patients with cryptococcal meningitis and cryptococcosis-associated immune reconstitution inflammatory syndrome. J Infect Dis (2013) 1.18
Pathogenicity and immunogenicity of attenuated, nef-deleted HIV-1 strains in vivo. Retrovirology (2007) 1.17
HIV-1 escape from the CCR5 antagonist maraviroc associated with an altered and less-efficient mechanism of gp120-CCR5 engagement that attenuates macrophage tropism. J Virol (2011) 1.16
SeqHepB: a sequence analysis program and relational database system for chronic hepatitis B. Antiviral Res (2006) 1.16
Inhibition of telomerase activity by human immunodeficiency virus (HIV) nucleos(t)ide reverse transcriptase inhibitors: a potential factor contributing to HIV-associated accelerated aging. J Infect Dis (2013) 1.16
Differential expression of CD163 on monocyte subsets in healthy and HIV-1 infected individuals. PLoS One (2011) 1.15
The pigtail macaque MHC class I allele Mane-A*10 presents an immundominant SIV Gag epitope: identification, tetramer development and implications of immune escape and reversion. J Med Primatol (2005) 1.15
Comparative efficacy of subtype AE simian-human immunodeficiency virus priming and boosting vaccines in pigtail macaques. J Virol (2006) 1.15
Virologically suppressed HIV patients show activation of NK cells and persistent innate immune activation. J Immunol (2012) 1.15
Rates of HIV immune escape and reversion: implications for vaccination. Trends Microbiol (2008) 1.14
Biomarkers of immune dysfunction following combination antiretroviral therapy for HIV infection. Biomark Med (2011) 1.14